期刊文献+

PPARγ的翻译后修饰 被引量:1

Posttranslational Modifications of Peroxisome Proliferator-activated Receptor γ
下载PDF
导出
摘要 过氧化物酶体增殖物激活受体γ(peroxisome proliferator-activated receptor gamma,PPARγ)是一种配体依赖性核转录因子,它具有调控细胞分化、脂肪代谢、糖代谢及炎症等多种生物学功能.机体对PPARγ转录活性的调控方式是多种多样的,包括蛋白表达水平、配体以及转录辅助因子等不同层次上的调控.近年来众多证据揭示,蛋白翻译后修饰(posttranslational modifications,PTMs)是机体调节PPARγ转录活性的另一重要方式.目前,已报道的PPARγ翻译后修饰包括磷酸化、泛素化、SUMO化和亚硝基化等,它们能够改变蛋白构象、调控蛋白相互作用、改变受体与配体间的亲和力,从而调控PPARγ下游基因的转录.重要的是,PPARγ的翻译后修饰与一些疾病如糖尿病、动脉粥样硬化、肿瘤等密切相关.本文将主要围绕PPARγ的各种翻译后修饰及其在疾病的发生、发展和治疗中的意义作一综述. Peroxisome proliferator-activated receptor γ(PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors.PPARγ regulates various biological processes such as cell differentiation,lipid metabolism,glucose metabolism and inflammation.It is acknowledged that the transcriptional activity of PPARγ may be fine-tuned by several mechanisms in vivo.For example,the expression level of PPARγ,the availability of its ligand and the association between PPARγ and corepressor/coactivator have been demonstrated to be able to regulate PPARγ activation.In addition,mounting evidence has defined posttranslational modifications(PTMs) as a novel essential factor tightly modulating PPARγ activation recently.Several PTMs of PPARγ including phosphorylation,ubiquitination,sumoylation and S-nitrosylation,might regulate its target genes by tuning protein conformation,protein-protein interactions and the affinity between the receptor and ligand.Importantly,there are some potential links between PTMs of PPARγ and the pathogenesis of several diseases such as diabetes,atherosclerosis and tumor.This review summarized the main characteristics of several PTMs of PPARγ,and highlighted the significance of PTMs in the occurrence,development and treatment of diseases.
出处 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2012年第8期685-691,共7页 Chinese Journal of Biochemistry and Molecular Biology
基金 国家自然科学基金(No.91013015 No.81121062) 江苏省自然科学基金(BK2010049)资助项目~~
关键词 过氧化物酶体增殖物激活受体Γ 转录活性 翻译后修饰 疾病 peroxisome proliferator-activated receptor ~/ transcriptional activity posttranslationalmodifications diseases
  • 相关文献

参考文献44

  • 1Tontonoz P, Spiegelman B M. Fat and beyond: the diverse biology of PPARγ[J].Annu Rev Bioehem, 2008, 77 ( 1 ) :289-312.
  • 2Lehrke M, Lazar MA. The many faces of PPARγ [ J ]. Cell, 2005, 123 (6) : 993-999.
  • 3Wan Y. PPARγ in bone homeostasis [J]. Trends Endocrinol Metab,2010, 21(12) : 722-728.
  • 4Klotz L, Burgdoff S, Dani I, et al. The nuclear receptor PPAγ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity [J].J Exp Med, 2009, 206( 10): 2079-2089.
  • 5Beekum O V, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR~,: fine-tuning the metabolic master regulator [J]. Obesity (Silver Spring) , 2009, 17(2) : 213-219.
  • 6Hu E, Kim J B, Sarraf P, et ul. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ [J].Science, 1996,274 (5295) :2100-2103.
  • 7Gelman L, Michalik L, Desvergne B, et al. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors [J]. Curt Opin Cell Biol, 2005, 17(2) : 216-222.
  • 8lankova I, Petersen RK, Annicotte J, et al. Peroxisome proliferator-activated receptor γ recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis [ J]. Mol Endoeriaol, 2006, 20(7) : 1494-1505.
  • 9Compe E, Drane P, Laurent C, et al. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations [ J]. Mol Cell Biol, 2005, 25(14) : 6065-6076.
  • 10Helenius K, Yang Y, Alasaari J, et al. Mat1 inhibits peroxisome proliferator-aetivated receptor "y-mediated adipoeyte differentiation [J]. Mol Cell Biol, 2009, 29(2) : 315-323.

二级参考文献33

  • 1Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk[J]. Am J Clin Nutr, 2003, 78 (3Suppl) :559s-569s.
  • 2Tamimi R M, Hankinson S E, Campos H, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer[J]. Am J Epidemiol, 2005,161(2) : 153-160.
  • 3Toniolo P, Van Kappel A L, Akhmedkhanov A, et al. Serum Carotenoids and Breast Cancer [ J]. Am J Epidemiol, 2001, 153 (12) : 1142-1147.
  • 4Shultz T D, Chew B P, Seaman W R, et al. Inhibitory effect of conjugated dienoic derivatives of linoleic acid and beta-carotene on the in vitro growth of human cancer cells[J]. Cancer Lett, 1992, 63 (2) : 125-133.
  • 5Prakash P, Russell R M, Krinsky N I. In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids [ J ]. J Nutr, 2001, 131(5) : 1574-1580.
  • 6Theocharis S, Kanelli H, Politl E, et al. Expression of peroxisome proliferator activated receptor-gamma in non-small cel1 lung carcinoma: correlation with histological type and grade [ ] ]. Lung Cancer, 2002, 36(3):249-255.
  • 7Pandhare J, Cooper S K, Phang J M. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-actived receptor gamma-dependent and -independent mechanisms[J]. ] Biol Chem, 2006, 281(4) :2044-2052.
  • 8Lu J, Imamura K, Nomura S, et al. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice[ J]. Cancer Res, 2005, 65 ( 11 ) :4769-4774.
  • 9Knight B, Yeap B B, Yeoh G C, et al. Inhibition of adult liver progenitor ( oval ) cell growth and wiability by an agonist of the peroxisome proliferator activated receptor (PPAR)family member {gamma } , but not { alpha} or { delta} [ J ]. Carcinogenesis, 2005, 26 (10) : 1782-1792.
  • 10Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma[J]. Mol Cell, 1998, 1 (3) :465-470.

同被引文献1

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部